New cycloartane triterpenoids from Dysoxylum malabaricum and their cytotoxic evaluation
[Display omitted] •Four cycloartane type triterpenoids (1–4) were isolated from the bark of Dysoxylum malabaricum.•Dereplication strategy was used to identify new compounds (3 and 4).•Evaluated for cytotoxicity against a panel of cancer cell lines and compound 3 was found to be the most cytotoxic (I...
Gespeichert in:
Veröffentlicht in: | Steroids 2023-12, Vol.200, p.109315-109315, Article 109315 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•Four cycloartane type triterpenoids (1–4) were isolated from the bark of Dysoxylum malabaricum.•Dereplication strategy was used to identify new compounds (3 and 4).•Evaluated for cytotoxicity against a panel of cancer cell lines and compound 3 was found to be the most cytotoxic (IC50 14 µM).
The cytotoxic dichloromethane-methanol bark extract of Dysoxylum malabaricum was subjected to bioassay-guided fractionation, followed by systematic dereplication to focus on the identification of new compounds. From the bark of Dysoxylum malabaricum, two new cycloartane-type triterpenoids were isolated in addition to two previously known triterpenoids. The structures and absolute configurations of the isolated compounds were elucidated unambiguously via NMR, HRESIMS data, and electronic circular dichroism calculations. The isolated compounds were tested for their cytotoxic potential against the panel of breast, lung, and hypopharynx cancer cell lines and displayed notable cytotoxicity against breast cancer cell lines. Compound 3 exhibited the most potent cytotoxic effect with an IC50 14 µM against MCF-7 cell lines and induced cell cycle arrest. Through western blot and cell cycle analysis, it was revealed that compound 3 halts the G0/G1 phase of the cell cycle by inhibiting CDC20 and CDC25 enzymes. |
---|---|
ISSN: | 0039-128X 1878-5867 |
DOI: | 10.1016/j.steroids.2023.109315 |